JP2007505942A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007505942A5 JP2007505942A5 JP2006527948A JP2006527948A JP2007505942A5 JP 2007505942 A5 JP2007505942 A5 JP 2007505942A5 JP 2006527948 A JP2006527948 A JP 2006527948A JP 2006527948 A JP2006527948 A JP 2006527948A JP 2007505942 A5 JP2007505942 A5 JP 2007505942A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- cycloalkyl
- aminoalkyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 Heterocycloalkyloxy Chemical group 0.000 claims description 65
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 52
- 125000003118 aryl group Chemical group 0.000 claims description 49
- 125000001072 heteroaryl group Chemical group 0.000 claims description 49
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 49
- 125000000217 alkyl group Chemical group 0.000 claims description 48
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 48
- 125000002252 acyl group Chemical group 0.000 claims description 42
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 42
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 42
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 40
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 38
- 125000003342 alkenyl group Chemical group 0.000 claims description 36
- 125000000304 alkynyl group Chemical group 0.000 claims description 36
- 125000001188 haloalkyl group Chemical group 0.000 claims description 36
- 125000004442 acylamino group Chemical group 0.000 claims description 33
- 125000004104 aryloxy group Chemical group 0.000 claims description 33
- 125000003545 alkoxy group Chemical group 0.000 claims description 30
- 125000003282 alkyl amino group Chemical group 0.000 claims description 30
- 229910052736 halogen Inorganic materials 0.000 claims description 30
- 150000002367 halogens Chemical class 0.000 claims description 30
- 125000001424 substituent group Chemical group 0.000 claims description 27
- 125000001769 aryl amino group Chemical group 0.000 claims description 26
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 25
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 24
- 125000004171 alkoxy aryl group Chemical group 0.000 claims description 24
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 24
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 24
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 24
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 24
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 24
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 24
- 125000000262 haloalkenyl group Chemical group 0.000 claims description 24
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 24
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 24
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 24
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 23
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 22
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 19
- 125000004465 cycloalkenyloxy group Chemical group 0.000 claims description 18
- 125000000232 haloalkynyl group Chemical group 0.000 claims description 18
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 14
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims description 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 6
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 6
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 6
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910021645 metal ion Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 108010033040 Histones Proteins 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 7
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 7
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 7
- 239000012472 biological sample Substances 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 241000283707 Capra Species 0.000 claims 4
- 102000003964 Histone deacetylase Human genes 0.000 claims 4
- 108090000353 Histone deacetylase Proteins 0.000 claims 4
- 239000013068 control sample Substances 0.000 claims 4
- 208000026278 immune system disease Diseases 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 238000001514 detection method Methods 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000000144 pharmacologic effect Effects 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000005806 3,4,5-trimethoxybenzyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1C([H])([H])* 0.000 claims 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000003120 Angiofibroma Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 241000222122 Candida albicans Species 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000003495 Coccidiosis Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 208000005819 Dystonia Musculorum Deformans Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims 1
- 208000001799 Hereditary Optic Atrophies Diseases 0.000 claims 1
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- 102100039996 Histone deacetylase 1 Human genes 0.000 claims 1
- 102100038715 Histone deacetylase 8 Human genes 0.000 claims 1
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 claims 1
- 101001032118 Homo sapiens Histone deacetylase 8 Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010023076 Isosporiasis Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 208000004554 Leishmaniasis Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000002903 Thalassemia Diseases 0.000 claims 1
- 206010044074 Torticollis Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 201000005485 Toxoplasmosis Diseases 0.000 claims 1
- 241000223105 Trypanosoma brucei Species 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 208000002353 alcoholic hepatitis Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 229940095731 candida albicans Drugs 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000006517 essential tremor Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000018197 inherited torticollis Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 201000003142 neovascular glaucoma Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 229920000155 polyglutamine Polymers 0.000 claims 1
- 108010040003 polyglutamine Proteins 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000001148 spastic effect Effects 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 208000018724 torsion dystonia Diseases 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50421403P | 2003-09-22 | 2003-09-22 | |
| US60/504,214 | 2003-09-22 | ||
| US53089003P | 2003-12-22 | 2003-12-22 | |
| US60/530,890 | 2003-12-22 | ||
| PCT/SG2004/000307 WO2005028447A1 (en) | 2003-09-22 | 2004-09-21 | Benzimidazole derivates: preparation and pharmaceutical applications |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007505942A JP2007505942A (ja) | 2007-03-15 |
| JP2007505942A5 true JP2007505942A5 (enExample) | 2011-07-28 |
| JP5042626B2 JP5042626B2 (ja) | 2012-10-03 |
Family
ID=34381112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006527948A Expired - Fee Related JP5042626B2 (ja) | 2003-09-22 | 2004-09-21 | ベンズイミダゾール誘導体：製造及び医薬適用 |
Country Status (14)
| Country | Link |
|---|---|
| US (7) | US7781595B2 (enExample) |
| JP (1) | JP5042626B2 (enExample) |
| KR (1) | KR101127201B1 (enExample) |
| AR (1) | AR046411A1 (enExample) |
| AT (1) | ATE472534T1 (enExample) |
| BR (1) | BRPI0414581C1 (enExample) |
| CA (1) | CA2539766C (enExample) |
| DE (1) | DE602004027932D1 (enExample) |
| DK (1) | DK1673349T3 (enExample) |
| MY (1) | MY142589A (enExample) |
| NZ (1) | NZ545864A (enExample) |
| PT (1) | PT1673349E (enExample) |
| TW (1) | TWI349664B (enExample) |
| WO (1) | WO2005028447A1 (enExample) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2306880T3 (es) | 2002-03-13 | 2008-11-16 | Janssen Pharmaceutica Nv | Derivados de sulfonilamino como inhibidores novedosos de la histona desacetilasa. |
| EA007270B1 (ru) | 2002-03-13 | 2006-08-25 | Янссен Фармацевтика Н.В. | Пиперазинил-, пиперидинил- и морфолинилпроизводные как новые ингибиторы гистондеацетилазы |
| CA2476067C (en) | 2002-03-13 | 2011-09-20 | Janssen Pharmaceutica N.V. | Carbonylamino-derivatives as novel inhibitors of histone deacetylase |
| AU2003218737B2 (en) | 2002-03-13 | 2008-04-10 | Janssen Pharmaceutica N.V. | Inhibitors of histone deacetylase |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7250514B1 (en) | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| KR20050122210A (ko) | 2003-03-17 | 2005-12-28 | 다케다 샌디에고, 인코포레이티드 | 히스톤 탈아세틸화 효소 억제제 |
| KR101127201B1 (ko) | 2003-09-22 | 2012-04-12 | 에스*바이오 피티이 리미티드 | 벤즈이미다졸 유도체와 그의 제조방법 및 약학적 적용 |
| PL1781639T3 (pl) | 2004-07-28 | 2012-07-31 | Janssen Pharmaceutica Nv | Podstawione pochodne indolilo-alkiloaminowe jako nowe inhibitory deacetylazy histonowej |
| UA86066C2 (ru) | 2004-07-28 | 2009-03-25 | Янссен Фармацевтика Н.В. | Производные замещенного пропенилпиперазина как ингибиторы гистондеацетилазы |
| JP2008524246A (ja) | 2004-12-16 | 2008-07-10 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| US7666880B2 (en) | 2005-03-21 | 2010-02-23 | S*Bio Pte Ltd. | Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications |
| GB0509223D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| GB0509225D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of enzymatic activity |
| WO2006122319A2 (en) | 2005-05-11 | 2006-11-16 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| AU2006248938B2 (en) | 2005-05-18 | 2011-09-29 | Janssen Pharmaceutica N.V. | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| ZA200800901B (en) | 2005-07-14 | 2010-05-26 | Takeda San Diego Inc | Histone deacetylase inhibitors |
| DK1937650T3 (da) * | 2005-09-08 | 2011-10-03 | S Bio Pte Ltd | Heterocykliske forbindelser |
| CA2540459C (en) * | 2005-09-08 | 2014-02-18 | S*Bio Pte Ltd | Benzimidazole compounds and uses in treating proliferative disorders |
| JP2007077085A (ja) * | 2005-09-15 | 2007-03-29 | Univ Of Tokyo | Ｈｄａｃ阻害活性を有する新規置換ヒドロキサム酸誘導体 |
| EP1943232B1 (en) | 2005-10-27 | 2011-05-18 | Janssen Pharmaceutica NV | Squaric acid derivatives as inhibitors of histone deacetylase |
| BRPI0620040A2 (pt) * | 2005-12-19 | 2011-10-25 | Methylgene Inc | inibidores de histona desacetilase para realçar a atividade de agentes antifúngicos |
| JP5247470B2 (ja) | 2006-01-19 | 2013-07-24 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストンデアセチラーゼのインヒビターとしてのピリジン及びピリミジン誘導体 |
| US8101616B2 (en) | 2006-01-19 | 2012-01-24 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| DK1979328T3 (da) | 2006-01-19 | 2013-03-25 | Janssen Pharmaceutica Nv | Pyridin- og pyrimidinderivater i deres egenskab af histondeacetylasehæmmere |
| DE602007001190D1 (de) | 2006-01-19 | 2009-07-09 | Janssen Pharmaceutica Nv | Aminophenylderivate als neue inhibitoren von histondeacetylase |
| US7834011B2 (en) | 2006-01-19 | 2010-11-16 | Janssen Pharmaceutica N.V. | Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase |
| CA2635015C (en) | 2006-01-19 | 2014-06-03 | Janssen Pharmaceutica N.V. | Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase |
| WO2007109178A2 (en) | 2006-03-16 | 2007-09-27 | Pharmacyclics, Inc. | Indole derivatives as inhibitors of histone deacetylase |
| ATE479678T1 (de) * | 2006-03-31 | 2010-09-15 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyridine als modulatoren des histamin-h4-rezeptors |
| WO2007117399A2 (en) * | 2006-03-31 | 2007-10-18 | Janssen Pharmaceutica N.V. | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor |
| ES2561835T3 (es) | 2006-09-20 | 2016-03-01 | Mei Pharma, Inc. | Compuestos hidroxamato de imidazo[1,2-a]piridina que son inhibidores de la histona desacetilasa |
| GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| JP5043120B2 (ja) | 2006-10-30 | 2012-10-10 | クロマ セラピューティクス リミテッド | ヒストンデアセチラーゼの阻害剤としてのヒドロキサメート |
| MX2009006327A (es) * | 2006-12-15 | 2009-06-23 | Novartis Ag | Compuestos heterociclicos y metodos de uso de los mismos. |
| MX2009006542A (es) * | 2006-12-19 | 2009-06-30 | Methylgene Inc | Inhibidores de histona desacetilasa y sus profarmacos. |
| ES2703592T3 (es) * | 2007-03-07 | 2019-03-11 | Mei Pharma Inc | Combinación de agente anticancerígeno de bencimidazol y un segundo agente anticancerígeno |
| DE102007037579B4 (de) | 2007-08-09 | 2012-05-16 | Emc Microcollections Gmbh | Neue Benzimidazol-2-yl-alkylamine und ihre Anwendung als mikrobizide Wirkstoffe |
| US8084466B2 (en) * | 2007-12-18 | 2011-12-27 | Janssen Pharmaceutica Nv | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor |
| US8987468B2 (en) * | 2008-02-04 | 2015-03-24 | The Translational Genomics Research Institute | Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives |
| CN101990433B (zh) | 2008-02-07 | 2014-11-05 | 马萨诸塞眼科耳科诊所 | 提高Atoh1表达的化合物 |
| EP2265590B8 (en) | 2008-04-15 | 2016-07-27 | Pharmacyclics LLC | Selective inhibitors of histone deacetylase |
| US20110288070A1 (en) * | 2008-05-05 | 2011-11-24 | ROGERS Kathryn | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
| US9371311B2 (en) | 2008-06-30 | 2016-06-21 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine derivatives |
| WO2010039697A2 (en) * | 2008-09-30 | 2010-04-08 | Gilead Sciences, Inc. | Selective inhibition of histone deacetylases 1 and 2 as a treatment for cardiac hypertrophy |
| GB0903480D0 (en) | 2009-02-27 | 2009-04-08 | Chroma Therapeutics Ltd | Enzyme Inhibitors |
| EP2305643A1 (en) | 2009-10-02 | 2011-04-06 | Ikerchem, S.L. | New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers |
| JP2013508461A (ja) * | 2009-10-27 | 2013-03-07 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 脂肪酸シンターゼ阻害剤としてのベンズイミダゾール |
| CN101881735B (zh) * | 2010-06-11 | 2011-11-16 | 赵永秀 | 尿液中百草枯的检测方法 |
| JP5782234B2 (ja) * | 2010-06-16 | 2015-09-24 | チャイナ メディカル ユニヴァーシティーＣｈｉｎａ Ｍｅｄｉｃａｌ Ｕｎｉｖｅｒｓｉｔｙ | ベンゾイミダゾール化合物およびその使用 |
| EP2397471A1 (en) * | 2010-06-16 | 2011-12-21 | China Medical University | Benzimidazole compounds and their use |
| ES2616238T3 (es) | 2010-10-06 | 2017-06-12 | Glaxosmithkline Llc, Corporation Service Company | Derivados de bencimidazol como inhibidores de PI3 quinasa |
| TW201245115A (en) | 2011-01-24 | 2012-11-16 | Chdi Foundation Inc | Histone deacetylase inhibitors and compositions and methods of use thereof |
| WO2013066832A1 (en) * | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| AR091773A1 (es) | 2012-07-16 | 2015-02-25 | Chdi Foundation Inc | Inhibidores de la histona desacetilasa y composiciones y sus metodos de uso |
| CN103755595A (zh) * | 2012-12-25 | 2014-04-30 | 中南大学 | 异羟肟酸类衍生物及其应用 |
| RS59909B1 (sr) | 2013-03-06 | 2020-03-31 | Janssen Pharmaceutica Nv | Benzoimidazol-2-il pirimidinski modulatori histaminskog h4 receptora |
| WO2015054099A1 (en) | 2013-10-08 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors |
| ES2862126T3 (es) | 2013-10-10 | 2021-10-07 | Acetylon Pharmaceuticals Inc | Compuestos de pirimidín-hidroxiamida como inhibidores de histona desacetilasa |
| US10660890B2 (en) | 2013-10-24 | 2020-05-26 | National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) | Treatment of polycystic diseases with an HDAC6 inhibitor |
| ES2806258T3 (es) | 2013-12-03 | 2021-02-17 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona desacetilasa y fármacos inmunomoduladores |
| SG11201700094TA (en) | 2014-07-07 | 2017-02-27 | Acetylon Pharmaceuticals Inc | Treatment of leukemia with histone deacetylase inhibitors |
| RU2700703C2 (ru) * | 2014-10-28 | 2019-09-19 | Сионоги Энд Ко., Лтд. | Гетероциклическое производное, обладающее активирующей ampk активностью |
| US9937174B2 (en) | 2014-12-05 | 2018-04-10 | University of Modena and Reggio Emilia | Combinations of histone deacetylase inhibitors and bendamustine |
| EP3932914A1 (en) | 2015-03-13 | 2022-01-05 | Valo Health, Inc. | Alpha-cinnamide compounds and compositions as hdac8 inhibitors |
| CA2984971A1 (en) | 2015-05-11 | 2016-11-17 | Kancera Ab | Benzimidazole derivates useful as inhibitors of mammalian histone deacetylase activity |
| US10272084B2 (en) | 2015-06-01 | 2019-04-30 | Regenacy Pharmaceuticals, Llc | Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy |
| KR20170049279A (ko) * | 2015-10-28 | 2017-05-10 | 엘지전자 주식회사 | 이동 단말기 |
| CA3007025A1 (en) | 2015-12-22 | 2017-06-29 | Kancera Ab | Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity |
| WO2017184774A1 (en) | 2016-04-19 | 2017-10-26 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors, alone or in combination with btk inhibitors, for treating chronic lymphocytic leukemia |
| AR108257A1 (es) | 2016-05-02 | 2018-08-01 | Mei Pharma Inc | Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas |
| TWI659949B (zh) * | 2016-05-16 | 2019-05-21 | 臺北醫學大學 | 組蛋白去乙醯酶6抑制劑及其用途 |
| JP6850911B2 (ja) * | 2017-06-02 | 2021-03-31 | 瀋陽化工研究院有限公司Ｓｈｅｎｙａｎｇ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｃｈｅｍｉｃａｌ Ｉｎｄｕｓｔｒｙ Ｃｏ．，Ｌｔｄ． | ビニルアレーン誘導体およびその使用 |
| CN110950848B (zh) * | 2018-09-27 | 2024-03-26 | 徐诺药业 | 新型氨基吡唑类衍生物的合成与应用 |
| WO2020097400A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof |
| EP3876930A4 (en) | 2018-11-07 | 2022-07-20 | Dana-Farber Cancer Institute, Inc. | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF |
| EP3876939A4 (en) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| WO2021217180A1 (en) | 2020-04-22 | 2021-10-28 | Johnson Matthey Public Limited Company | Novel forms of pracinostat dihydrochloride |
| BR112022022409A2 (pt) | 2020-05-06 | 2023-02-07 | Ajax Therapeutics Inc | 6-heteroarilóxi benzimidazóis e azabenzimidazóis como inibidores de jak2 |
| WO2021251565A1 (en) * | 2020-06-12 | 2021-12-16 | Hk Inno.N Corporation | Pharmaceutical composition comprising benzimidazole derivative compound |
| CA3187867A1 (en) * | 2020-07-03 | 2022-01-06 | Nihon Nohyaku Co., Ltd. | Anticoccidial agent and method for using the same |
| WO2022140527A1 (en) | 2020-12-23 | 2022-06-30 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| WO2023086320A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of jak2 |
| CA3234638A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| KR102730905B1 (ko) * | 2022-05-03 | 2024-11-15 | 충북대학교 산학협력단 | 신규한 n-히드록시프로펜아미드 화합물 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
| CN115368239B (zh) * | 2022-09-01 | 2024-04-26 | 南开大学 | 一种肉桂酸酯衍生物的合成及其制药应用 |
| KR102541577B1 (ko) * | 2022-10-21 | 2023-06-13 | 주식회사 넥스트젠바이오사이언스 | S1pr1과 s1pr4에 대한 기능적 저해제로 작용하는 원형 탈모증의 예방 또는 치료용 약학적 조성물 |
| CN118234492A (zh) | 2022-10-21 | 2024-06-21 | 次代生物科学株式会社 | 具有针对s1pr1和s1pr4的功能性抑制剂作用的用于预防或治疗圆形脱发症的药物组合物 |
| CN116440130B (zh) * | 2023-04-12 | 2025-07-25 | 西藏农牧学院 | 苯并噻唑化合物在制备抑制白色念珠菌产品中的应用 |
| IL324858A (en) * | 2023-05-30 | 2026-01-01 | 16380026 Canada Inc | Cyp26b1 inhibitor compounds and methods of use thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2291749A1 (fr) * | 1974-11-20 | 1976-06-18 | Delalande Sa | Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique |
| CA2135173A1 (en) | 1992-05-20 | 1993-11-25 | Bruce E. Witzel | Ester derivatives of 4-aza-steroids |
| SE9804212D0 (sv) | 1998-12-04 | 1998-12-04 | Astra Pharma Prod | Compounds |
| IL144214A0 (en) * | 1999-01-13 | 2002-05-23 | Warner Lambert Co | Benzoheterocycles and their use as mek inhibitors |
| WO2001000207A1 (en) * | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| AU5636900A (en) | 1999-06-30 | 2001-01-31 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| AU6068600A (en) | 1999-07-16 | 2001-02-05 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
| DK1202724T3 (da) | 1999-07-16 | 2004-01-26 | Warner Lambert Co | Fremgangsmåde til behandling af kronisk smerte under anvendelse af mek-inhibitorer |
| GB9919558D0 (en) * | 1999-08-18 | 1999-10-20 | Hoechst Schering Agrevo Gmbh | Fungicidal compounds |
| CA2391952C (en) | 1999-11-23 | 2012-01-31 | Methylgene Inc. | Inhibitors of histone deacetylase |
| EP1162196A4 (en) | 1999-12-27 | 2003-04-16 | Japan Tobacco Inc | COMPOUNDS WITH JOINED CYCLES AND THEIR USE AS MEDICAMENTS |
| US6770666B2 (en) | 1999-12-27 | 2004-08-03 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| WO2002026696A1 (en) * | 2000-09-29 | 2002-04-04 | Prolifix Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
| CA2428191A1 (en) | 2000-11-07 | 2002-05-30 | Bristol-Myers Squibb Company | Acid derivatives useful as serine protease inhibitors |
| PA8535601A1 (es) * | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| CA2450555A1 (en) | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| WO2003066889A2 (en) | 2002-02-07 | 2003-08-14 | Axys Pharmaceuticals, Inc. | Assay for acytyltransferase or deacetylase activity |
| TWI343377B (en) | 2002-03-13 | 2011-06-11 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| WO2003077855A2 (en) * | 2002-03-13 | 2003-09-25 | Array Biopharma, Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| CA2484261A1 (en) * | 2002-04-16 | 2003-10-23 | Teijin Limited | Piperidine derivatives having ccr3 antagonism |
| DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| US7151096B2 (en) | 2003-03-05 | 2006-12-19 | Irm Llc | Cyclic compounds and compositions as protein kinase inhibitors |
| KR20050122210A (ko) | 2003-03-17 | 2005-12-28 | 다케다 샌디에고, 인코포레이티드 | 히스톤 탈아세틸화 효소 억제제 |
| KR101127201B1 (ko) | 2003-09-22 | 2012-04-12 | 에스*바이오 피티이 리미티드 | 벤즈이미다졸 유도체와 그의 제조방법 및 약학적 적용 |
| WO2005065681A1 (en) | 2003-12-19 | 2005-07-21 | Takeda San Diego, Inc. | N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer |
| WO2005066151A2 (en) | 2003-12-19 | 2005-07-21 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| WO2006101456A1 (en) | 2005-03-21 | 2006-09-28 | S*Bio Pte Ltd | Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors |
| DK1937650T3 (da) | 2005-09-08 | 2011-10-03 | S Bio Pte Ltd | Heterocykliske forbindelser |
| ES2703592T3 (es) | 2007-03-07 | 2019-03-11 | Mei Pharma Inc | Combinación de agente anticancerígeno de bencimidazol y un segundo agente anticancerígeno |
| SMT202000168T1 (it) | 2012-10-30 | 2020-05-08 | Mei Pharma Inc | Terapie di combinazione per il trattamento dei tumori chemioresistenti |
-
2004
- 2004-09-21 KR KR20067005698A patent/KR101127201B1/ko not_active Expired - Fee Related
- 2004-09-21 DK DK04775628T patent/DK1673349T3/da active
- 2004-09-21 NZ NZ545864A patent/NZ545864A/en not_active IP Right Cessation
- 2004-09-21 DE DE200460027932 patent/DE602004027932D1/de not_active Expired - Lifetime
- 2004-09-21 AR ARP040103390 patent/AR046411A1/es active IP Right Grant
- 2004-09-21 AT AT04775628T patent/ATE472534T1/de active
- 2004-09-21 MY MYPI20043871 patent/MY142589A/en unknown
- 2004-09-21 TW TW093128611A patent/TWI349664B/zh not_active IP Right Cessation
- 2004-09-21 WO PCT/SG2004/000307 patent/WO2005028447A1/en not_active Ceased
- 2004-09-21 JP JP2006527948A patent/JP5042626B2/ja not_active Expired - Fee Related
- 2004-09-21 BR BRPI0414581A patent/BRPI0414581C1/pt not_active IP Right Cessation
- 2004-09-21 CA CA 2539766 patent/CA2539766C/en not_active Expired - Fee Related
- 2004-09-21 US US10/572,958 patent/US7781595B2/en not_active Expired - Fee Related
- 2004-09-21 PT PT04775628T patent/PT1673349E/pt unknown
-
2010
- 2010-06-14 US US12/814,964 patent/US8551988B2/en not_active Expired - Fee Related
-
2013
- 2013-09-03 US US14/016,990 patent/US9024029B2/en not_active Expired - Fee Related
-
2015
- 2015-02-20 US US14/627,418 patent/US9402829B2/en not_active Expired - Fee Related
-
2016
- 2016-06-10 US US15/178,742 patent/US9717713B2/en not_active Expired - Fee Related
-
2017
- 2017-06-02 US US15/612,670 patent/US10201527B2/en not_active Expired - Fee Related
-
2018
- 2018-12-14 US US16/221,186 patent/US10736881B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60220188T2 (de) | Hemmer des phosphattransports | |
| JP4685068B2 (ja) | 脈管形成阻害活性を有するアリール尿素 | |
| KR101559963B1 (ko) | Ａｔｐ-결합 카세트 수송자의 조절자 | |
| US9504683B2 (en) | Heteroaryl derivatives as CFTR modulators | |
| CA2699382C (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| JP4871257B2 (ja) | ２−フェニルプロピオン酸誘導体およびそれらを含有する医薬組成物 | |
| RU2007116150A (ru) | Полиморфные формы 6-[2-(метилкарбамоил)фенилсульфанил]-3-е-[2-[пиридин-2-ил)этенил]индазола | |
| JP2001523712A (ja) | Ｐｄｅ−ｉｖのベンゼンスルホンアミド阻害剤およびそれらの治療的使用 | |
| JP2009536969A (ja) | Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミド組成物 | |
| KR20140090231A (ko) | Atp-결합 카세트 수송체의 조절제 | |
| ZA200205660B (en) | Corticotropin releasing factor antagonists. | |
| KR20230149861A (ko) | 아픽사반 제제 | |
| WO2000031021A1 (fr) | INHIBITEURS DE PRODUCTION/DE SECRETION DE PROTEINE β-AMYLOIDE | |
| US9969701B2 (en) | Salts and co-crystals of lesinurad | |
| JP2018509446A (ja) | Ｎ−（５−シアノ−４−（（２−メトキシエチル）アミノ）ピリジン−２−イル）−７−ホルミル−６−（（４−メチル−２−オキソピペラジン−１−イル）メチル）−３，４−ジヒドロ−１，８−ナフチリジン−１（２ｈ）−カルボキサミドの粒子 | |
| JP2006510728A5 (enExample) | ||
| CN112135615B (zh) | 包含吲哚类化合物的肾病综合征治疗或预防剂 | |
| DE3884858T2 (de) | Phenol-thioalkylamide als Inhibitoren von 5-Lipoxygenase. | |
| ZA200602181B (en) | Benzimidazole derivatives: Preparation and pharmaceutical applications | |
| JP2007535554A5 (enExample) | ||
| US4940712A (en) | Derivatives of hydroxyprimidines as leukotriene synthesis inhibitors | |
| CN110483425B (zh) | 一种酰基硫脲类化合物及其制备方法与抗甲型流感病毒的应用 | |
| JP2009520018A5 (enExample) | ||
| WO2017216579A1 (en) | Autophagy inducer compounds | |
| US20040132743A1 (en) | Amorphous form of (-)-[2-[4-[(4-Chlorophenyl)-phenyl methyl]-1- piperazinyl] ethoxy] acetic acid dihydrochloride (levocetirizine dihydrochloride) |